Patents by Inventor Seiji KAMIOKA
Seiji KAMIOKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240148727Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: ApplicationFiled: January 12, 2024Publication date: May 9, 2024Applicant: Sumitomo Pharma Co., Ltd.Inventors: Seiji KAMIOKA, Hitoshi BAN, Naoaki SHIMADA, Wataru HIROSE, Akihiko ARAKAWA, Kazuto YAMAZAKI, Kenjiro HIRA
-
Patent number: 11911381Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: GrantFiled: May 23, 2022Date of Patent: February 27, 2024Assignee: Sumitomo Pharma Co., Ltd.Inventors: Seiji Kamioka, Hitoshi Ban, Naoaki Shimada, Wataru Hirose, Akihiko Arakawa, Kazuto Yamazaki, Kenjiro Hira
-
Publication number: 20230219970Abstract: The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.Type: ApplicationFiled: March 21, 2023Publication date: July 13, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Miki HASHIZUME
-
Patent number: 11639357Abstract: The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.Type: GrantFiled: July 31, 2020Date of Patent: May 2, 2023Assignee: Sumitomo Pharma Co., Ltd.Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Miki Hashizume
-
Patent number: 11564920Abstract: The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R1, R2, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR8 or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR8, and R8 is as defined herein.Type: GrantFiled: April 27, 2022Date of Patent: January 31, 2023Assignee: Sumitomo Pharma Co., Ltd.Inventors: Seiji Kamioka, Hitoshi Ban, Makoto Matsuoka, Wataru Hirose, Naoaki Shimada, Kento Hayashi, Hiroki Umehara
-
Publication number: 20230025065Abstract: The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R1, R2, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR8 or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR8, and R8 is as defined herein.Type: ApplicationFiled: November 29, 2021Publication date: January 26, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Seiji KAMIOKA, Hitoshi BAN, Makoto MATSUOKA, Wataru HIROSE, Naoaki SHIMADA, Kento HAYASHI, Hiroki UMEHARA
-
Publication number: 20220380365Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, Ring A is cycloalkylene or the like, L is single bond or the like, and R is methyl or the like, or a pharmaceutically acceptable salt thereof, which has an anticancer effect by inhibiting the binding between a MLL fusion protein that is fused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: ApplicationFiled: September 25, 2020Publication date: December 1, 2022Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji KAMIOKA, Naoaki SHIMADA, Wataru HIROSE, Hitoshi BAN
-
Publication number: 20220288072Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: ApplicationFiled: May 23, 2022Publication date: September 15, 2022Applicant: Sumitomo Pharma Co., Ltd.Inventors: Seiji KAMIOKA, Hitoshi BAN, Naoaki SHIMADA, Wataru HIROSE, Akihiko ARAKAWA, Kazuto YAMAZAKI, Kenjiro HIRA
-
Publication number: 20220273649Abstract: The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R1, R2, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR8 or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR8, and R8 is as defined herein.Type: ApplicationFiled: April 27, 2022Publication date: September 1, 2022Applicant: Sumitomo Pharma Co., Ltd.Inventors: Seiji KAMIOKA, Hitoshi BAN, Makoto MATSUOKA, Wataru HIROSE, Naoaki SHIMADA, Kento HAYASHI, Hiroki UMEHARA
-
Patent number: 11414394Abstract: A process for producing a hydrate of a hydrochloride salt of 2,2?-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid of the formula: wherein the process comprises the following step: recrystallizing the hydrochloride salt of 2,2?-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid, in the presence of hydrochloric acid and a recrystallization solvent; wherein the recrystallization solvent is methanol, ethanol, 2-propanol, diethyl ether, ethyl acetate, benzene, toluene, acetone, dichloromethane, chloroform, hexane, dimethylformamide, acetonitrile, or water; or mixed solvent thereof.Type: GrantFiled: August 28, 2020Date of Patent: August 16, 2022Assignees: SUMITOMO PHARMA ONCOLOGY, INC., SUMITOMO PHARMA CO., LTD.Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Chiang Jia Li
-
Patent number: 11369605Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: GrantFiled: August 26, 2019Date of Patent: June 28, 2022Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji Kamioka, Hitoshi Ban, Naoaki Shimada, Wataru Hirose, Akihiko Arakawa, Kazuto Yamazaki, Kenjiro Hira
-
Patent number: 11325921Abstract: The present invention relates to the compound of formula (I) wherein p is 1 or 2, R1 is —CF3 or the like, R2a, R2b, R3a, and R3b are hydrogen atom or the like, X is —C(?O)—or the like, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: GrantFiled: March 29, 2019Date of Patent: May 10, 2022Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji Kamioka, Naoaki Shimada, Wataru Hirose, Hitoshi Ban, Akihiko Yokoyama
-
Publication number: 20210338668Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: ApplicationFiled: August 26, 2019Publication date: November 4, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji KAMIOKA, Hitoshi BAN, Naoaki SHIMADA, Wataru HIROSE, Akihiko ARAKAWA, Kazuto YAMAZAKI, Kenjiro HIRA
-
Publication number: 20210198283Abstract: The present invention relates to the compound of formula (Ia) wherein a-d and p are 1 or 2, R1-R4 are hydrogen atom or the like, and R18 is —CF3 or the like, or a pharmaceutically acceptable salt thereof, which has an anticancer effect by inhibiting the binding between a MLL fusion protein that is fused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: ApplicationFiled: August 7, 2019Publication date: July 1, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji KAMIOKA, Naoaki SHIMADA, Hitoshi BAN, Kazuto YAMAZAKI, Akihiko ARAKAWA, Wataru HIROSE
-
Patent number: 10934309Abstract: This invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [Therein, A is O, S, or N—R6; ring G is a 5-membered or 6-membered aromatic ring, etc., including 1-3 heteroatoms selected from O, S and N as constituent atoms; R1 and R2 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; and R6 is a hydrogen atom or an optionally-substituted C1-6 alkyl group, etc.].Type: GrantFiled: December 27, 2018Date of Patent: March 2, 2021Assignee: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Hitoshi Ban, Seiji Kamioka, Shoukou Ri, Tomoyuki Furuta, Hiroyuki Kitano, Chiang Jia Li
-
Publication number: 20210024547Abstract: The present invention relates to the compound of formula (I) wherein p is 1 or 2, R1 is —CF3 or the like, R2a, R2b, R3a, and R3b are hydrogen atom or the like, X is —C(?O)—or the like, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: ApplicationFiled: March 29, 2019Publication date: January 28, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji KAMIOKA, Naoaki SHIMADA, Wataru HIROSE, Hitoshi BAN, Akihiko YOKOYAMA
-
Publication number: 20210002290Abstract: The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.Type: ApplicationFiled: July 31, 2020Publication date: January 7, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hitoshi BAN, Seiji Kamioka, Yusuke Sawayama, Miki Hashizume
-
Publication number: 20200392098Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O)B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.Type: ApplicationFiled: August 28, 2020Publication date: December 17, 2020Applicants: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Chiang Jia LI
-
Patent number: 10815241Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: GrantFiled: January 21, 2020Date of Patent: October 27, 2020Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji Kamioka, Hitoshi Ban, Naoaki Shimada, Wataru Hirose, Akihiko Arakawa, Kazuto Yamazaki, Kenjiro Hira
-
Patent number: 10807993Abstract: The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.Type: GrantFiled: March 3, 2020Date of Patent: October 20, 2020Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Miki Hashizume